PAR-21-082 - NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44 Clinical Trial Required) is used for the submission of applications to the following Notices of Special Interest (NOSIs)
Expired NOSIs
| Title | Notice Number | Organization | Release Date | Expiration Date | Activity Code(s) |
|---|---|---|---|---|---|
| Notice of Special Interest (NOSI): Advancing Biomedical Research in Pulmonary Non-Tuberculous Mycobacterial (NTM) Infections | NOT-AI-23-050 | NIAID | Jun 27, 2023 | Sep 9, 2025 | R21, R41/R42, R43/R44, R01, U44 |
| Notice of Special Interest (NOSI): Promoting Research and Development of Vaccines Against Enteric Viruses | NOT-AI-23-048 | NIAID | Jun 15, 2023 | Sep 9, 2025 | R01, R43/R44, U44, R41/R42, R21 |
| Notice of Special Interest (NOSI): Advancing Research Needed to Develop a Coccidioidomycosis (Valley fever) Vaccine | NOT-AI-23-031 | NIAID | Feb 23, 2023 | Sep 9, 2025 | R01, R41/R42, R43/R44, R21, U44 |
| Notice of Special Interest (NOSI): Accelerating Progress in Celiac Disease Research | NOT-AI-22-004 | NIAID, NIAMS, NCCIH, NCI | Nov 23, 2021 | Jan 8, 2025 | R03, R21, U01, U44, R01, R34, P01, R61/R33 |
For technical issues E-mail OER Webmaster